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A basic understanding of growth cone dynamics and de-
velopmental events involving growth cones requires an un-
derstanding of the function and regulation of molecules as-
sociated with and released by growth cones. Rat sympathetic 
neurons in culture release a urokinase-like plasminogen ac-
tivator from their distal processes and/or growth cones (Pitt-
man, 1985a). When sympathetic neurons are grown in co-
cultures with heart cells, however, plasminogen activator 
activity is not detected. The absence of plasminogen acti-
vator activity in cocultures of sympathetic neurons and heart 
cells appears to be due to the release of an inhibitor of 
plasminogen activator by heart cells. This inhibitor has a 
molecular weight of approximately 50 kDa in the presence 
of SOS and apparent molecular weights of approximately 50 
and >2000 kDa under native conditions. A significant frac-
tion of the large-molecular-weight form of the inhibitor is 
converted to the smaller form following treatment with hepa-
rinase. Extremely stable complexes of 68 and 80 kDa are 
formed between the heart inhibitor and the plasminogen ac-
tivator, urokinase, such that the complexes withstand boiling 
in SDS/mercaptoethanol. The data are consistent with the 
formation of an 80 kDa urokinase-inhibitor complex in the 
presence of heparan sulfate proteoglycan and a 68 kDa com-
plex in the absence of heparan sulfate proteoglycan. A highly 
purified preparation of the heart inhibitor produces a 2- to 
3-fold increase in neurite outgrowth from sympathetic neu-
rons. These data indicate that the activity of the plasminogen 
activator released by sympathetic neurons can be regulated 
by a normal target tissue and that this regulation may result 
in increased neurite outgrowth from the neurons. 
Growth cones are actively involved in axonal pathfinding, neu-
rite outgrowth, and neuron-target cell interactions (Letourneau, 
1983; Goodman et al., 1984; Kater and Letourneau, 1985). 
Since molecules released by growth cones may play important 
roles in these events, a better understanding of growth cone 
function will be obtained once molecules released by growth 
cones are identified and characterized and their regulation de-
termined. Neurons of both the peripheral and central nervous 
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systems release the serine protease plasminogen activator (PA) 
(Krystosek and Seeds, 1981 a, 1984; Soreq and Miskin, 1983; 
Alvarez-Buyllaand Valinsky, 1985; Pittman, 1985), a significant 
fraction of which is released from the distal processes and/or 
growth cones (Krystosek and Seeds, 1984; Pittman, l 985a). Al-
though a definitive role for PA has not been found in the nervous 
system, it has been suggested that it may be involved in granule 
cell migration (Krystosek and Seeds, 198 la; Moonen et al., 1982; 
Soreq and Miskin, 1983), Schwann cell movement (Krystosek 
and Seeds, 1984), and Schwann cell proliferation (Kalderon, 
1984). Because PA is released from growth cones (Krystosek 
and Seeds, 198lb, 1984; Pittman, 1985a), it may be that PA 
activates plasminogen in the local environment of the growth 
cone and the plasmin thus formed helps the growing neurite 
degrade components of the extracellular matrix through which 
it must grow (e.g., see Tosney and Landmesser, 1985). If PA is 
involved in events associated with neurite outgrowth, then it 
might be expected that once the neurite reached its appropriate 
target that a decrease in PA activity would occur. 
Proteases are regulated by specific activators and inhibitors. 
A balance between proteolytic and inhibitory activities may be 
an important factor in various cellular events, including neu-
ronal development. An inhibitor of serine proteases (including 
PA) has recently been purified from glioma conditioned medium 
and has been shown to increase process outgrowth from neu-
roblastoma cells (Guenther et al., 1985; Monard, 1985). Several 
other eell types appear to release inhibitors of serine proteases 
(Eaton and Baker, 1983; Van Mourik et al., 1984), and although 
specific physiological functions have not been attributed to these 
inhibitors, their ability to bind to the active site of serine pro-
teases and form stable complexes would suggest that they are 
important regulators of cellular processes. 
Sympathetic neurons release a urokinase-like PA as well as a 
calcium-dependent metalloprotease (Pittman, l 985a). The pres-
ent study was undertaken to determine if the release of PA by 
sympathetic neurons was affected by culturing neurons in the 
presence of a target tissue, cardiac myocytes. These studies in-
dicate that little or no PA activity is present in cocultures of 
neurons and heart cells and that this is the result of an inhibitor 
of PA released by the heart cells. A preliminary account of this 
work has appeared (Pittman, 1984). 
Materials and Methods 
Materials 
The following drugs and reagents were used: fibrinogen (Calbiochem, 
San Diego), CH-Sepharose and lysine-Sepharose (Pharmacia, Piscata-
way, NJ), octyl-Sepharose, Sephadex G-100, Sepharose 6B, p-amino-
benzamidine agarose, trypsin, chymotrypsin, urokinase, thrombin, ther-
molysin, aminopeptidase M, heparin, and heparinase (Sigma Chemical 
Co., St. Louis). All other chemicals were reagent grade. 
Plasminogen was purified from human serum according to the method 
of Deutsch and Mertz ( 1970). 
Cell culture 
Neurons from sympathetic ganglia of neonatal rats were obtained by 
mechanical dissociation and trituration through a 20 gauge needle, fol-
lowed by preplating on tissue culture plastic for 2 hr to remove non-
neuronal cells. Neurons were grown on rat tail collagen in 24 well cluster 
dishes (2 cm2/well) in serum-free LI 5 C02 medium as previously de-
scribed (Pittman, 1985a). The medium was a modification (Wolinsky 
et al., 1985) ofN2 medium (Bottenstein et al., 1980) and was composed 
of LI 5 C02 medium containing stable and fresh vitamins (Hawrot and 
Patterson, 1979), insulin (5 µ.g/ml), transferrin (I 0 µ.g/ml), progesterone 
(20 nM), putrescine (100 µ.M), selenium (30 nM), and 7S NGF (250 ng/ 
ml). 
Cultures of heart cells (a mixture of fibroblasts and myocytes) were 
established from atria and ventricles of neonatal rats by dissociating 
cells in 0.5% dispase (Boehringer Mannheim, Indianapolis) and 0.1 % 
collagenase (Worthington, Malvern, PA) in calcium- and magnesium-
free Hank's buffered saline. Cultures were grown for 1-3 din Ll5 C02 
medium containing stable and fresh vitamins {Hawrot and Patterson, 
1979) and 10% fetal calf serum. The cells were then switched to the 
same serum-free medium used for neurons with the exception that NGF 
was omitted and 200 ng/ml EGF included. Highly enriched cultures of 
cardiac fibroblasts and myocytes were obtained by modifications of 
established procedures (Mohamed et al., 1983). Cells were dissociated 
and preplated for l hr on tissue culture plastic, followed by a second 
preplating on tissue culture plastic for 2 hr. Nonadherent cells from the 
second preplating were plated on tissue culture plastic. These cells were 
highly enriched in cardiac myocytes (>80% of the cells beat sponta-
neously after 2-3 d in culture). The cells that attached during the first 
preplating were highly enriched in fibroblast- like cells, while the cells 
that attached during the second preplating were a mixture offibroblast-
like cells and myocytes. The cultures enriched in myocytes and fibro-
blasts were grown in serum-free medium for the duration of the exper-
iments. 
Cocultures of sympathetic neurons and heart cells were established 
by plating mechanically dissociated neurons on monolayers of my-
ocytes, fibroblasts, or mixed cultures of heart cells in serum-free me-
dium. 
Gel electrophoresis assays for the PA inhibitor 
Inhibition method. Serum-free heart cell conditioned medium (CM) was 
mixed with SDS (2% final concentration) and electrophoresed in SDS 
slab gels containing 7.3% acrylamide, 0.31 % bisacrylamide, 0.11% gel-
atin, and 0.25 mg plasminogen. Electrophoresis was at a constant current 
of 9 mA at 4°C in an SDS buffer (Laemmli, 1970). SDS was removed 
following electrophoresis by washing the gel 3 times with 15 vol of 2% 
Triton X-100 (20-30 min each) while shaking at room temperature 
(RT). The gel was placed in 20 mM Tris, pH 7.5, containing 2 units/ml 
urokinase (UK) for 30 min at RT, followed by washing 4 times with 
buffer without UK and incubation for 12 hr at 30"C. Exposure of the 
gel to exogenously added UK resulted in the conversion of the plas-
minogen in the gel to plasmin, which in turn degraded the gelatin in 
the gel. Inhibitors of UK block the activation of plasminogen by UK 
in local areas of the gel and are visualized as bands of dark blue gelatin 
in a clear gel following protein staining with 0.1 % amido black. Inhib-
itors of either UK or plasmin would be detected using this assay. 
Complexformation with 125!-UK. Commercially available UK(Sigma 
Chemical Co.) was purified using a p-aminobenzamidine affinity column 
(Wun et al., 1982) to >99.9% purity (determined following SDS gel 
electrophoresis and silver staining) and iodinated with Na1251 using 
l,3,4,6-tetrachloro-3a,6a-diphenylglycouril (iodogen). Iodinated pro-
tein was separated from free iodine with a Sephadex G-25 column and 
stored at - 70°C for up to 3 weeks. Serum-free CM from heart cells, 
intact heart cells, or membranes prepared from heart cells were incu-
bated with '2'1-UK for 30-60 min at 30 or 37"C in complete serum-
free medium or 20 mM Tris-HCI, pH 7.5. Samples were then boiled in 
sample buffer containing 4% mercaptoethanol and 2% SDS for 5 min 
followed by SDS slab gel electrophoresis. Radiolabeled proteins were 
detected by autoradiography, and quantification was performed by cut-
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Table 1. Effect of heart cells on neuronal PA 
Condition 
Neuron alone culture" 
Heart alone cultureb 
Neuron + heart coculture•·b 
Neuron CM + heart CM 
means± 
PA activity 
0.81 + 0.13 
0.03 ± O.Q3 
0.04 ± 0.03 
0.01 ± 0.01 
the amount of PA activity by sympathetic neurons into 
the culture medium during a 24 hr period. The same culture medium used to 
determine activity in cultures of neuron alone and heart cell alone was also mixed 
together and incubated for45 min at 30°C prior to determining PA activity (neuron 
CM + heart CM group). 
0 Expressed per 5000 neurons plated. 
b Confluent 2 cm2 culture of heart cells. 
ting bands out of gels and determining radioactivity using a gamma 
counter. 
Blotting. Samples were prepared by adding SDS (2% final concentra-
tion) to serum-free CM from cells. Samples were run in 10 or 12% 
acrylamide gels at 4°C and 12 mA using a Laemmli buffer system 
(Laemmli, 1970). Following electrophoresis, SDS was removed from 
the gel by incubating in 2% Triton X-100 for l hr at RT, followed by 
washing 4-5 times in buffer (IO mM Tris/77 mM glycine, pH 8.3). Pro-
teins were electrophoretically transferred onto 0.45 µ.m nitrocellulose 
sheets in ice-cold buffer (no methanol present) at 9 5 V for 40 min using 
a Trans-Blot system (Bio-Rad, Richmond, CA). Nitrocellulose strips 
were incubated at RT for 1 hr in 20 mM Tris, 150 mM NaCl, 4 mM 
EDTA, 0.1% Tween-20, pH 7.4, to block nonspecific binding, followed 
by incubation for 6 hr at RT in buffer containing 0.02% Tween-20 and 
5 x 105 cpm/ml 1251-UK. The nitrocellulose was then washed 4-5 times 
over a period of l hr in buffer containing 0.02% Tween-20, followed 
by air drying and autoradiography. 
Assay for PA activity 
Plasminogen activator activity was quantitated using a modification of 
the method ofUnkeless et al. (1973), as previously described (Pittman, 
l 985a). In short, 20 µ.g fibrinogen (10' cpm) was added to each well of 
a 24 well dish (2 cm2/well) and dried under vacuum. The fibrinogen 
was converted to fibrin using thrombin, and assays were run at 37"C in 
0.5 ml of 0.1 M Tris-HCI, pH 8.1, containing 0.1 % gelatin, 2 µ.g human 
plasminogen, and 5-250 µ.l serum-free conditioned medium. Aliquots 
were removed, and radioactivity was determined after 1, 2, and 3 hr. 
Column chromatography 
Heparin-sepharose. CH-Sepharose 4B (1 gm) was swollen for 45 min 
in ice-cold 1 mM HCl followed by washing with 200 ml ice-cold l mM 
HCI. Grade II heparin, 0.7 gm (Sigma), was dissolved in 12 ml ofO.I 
M bicarbonate buffer containing 0.5 M NaCl, pH 8.2, and added to the 
CH-Sepharose. The mixture was shaken for 2 hr at 22°C and then for 
14 hr at 4"C. Excess reactive groups on the resin were blocked by in-
cubating with 50 mM Tris, 0.5 M NaCl, pH 8.0, for 2 hr. 
Samples of serum-free heart CM (2-200 ml) were loaded onto the 
heparin-Sepharose column {0.6 x 4.5 cm column bed) with a How rate 
of 1 ml/min. The vast majority of proteins passed through the column, 
including the form of the inhibitor that formed an 80 kDa complex with 
1251-UK. In a typical experiment, the column was then washed with 20 
ml of 50 mM Tris, pH 7.5, and then with 20 ml of 0.1 M NaCl in 50 
mM Tris, 20 ml of 0.3 M NaCl in 50 mM Tris, 5 ml of 0. 7 M NaCl in 
50 mM Tris, and 5 ml of 1.0 M NaCl in 50 mM Tris. Most of the inhibitor 
that formed the 68 kDa complex with 1251-UK was eluted at 0.7 M NaCl 
and a small amount at LO M NaCL 
For purification of the inhibitor, the fractions eluted from the heparin-
Sepharose column with 0. 7 and 1.0 M NaCl were adjusted to 0.5 M 
NaCl and reapplied to the heparin-Sepharose column equilibrated with 
0.5 M NaCl. The column was washed with 3 column volumes of0.5 M 
NaCl and the inhibitor was eluted from the column with 0.8 M NaCl. 
Gel filtration. Serum-free CM from heart cell cultures containing both 
fibroblasts and myocytes was concentrated 15-fold using an Amicon 
concentrator and loaded along with molecular-weight standards (amy-
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Figure 1. Inhibitors of PA released by cultures of heart cells. Serum-
free CM from heart cell cultures was electrophoresed in a polyacrylamide 
gel in which plasminogen and gelatin had been cross-linked. Following 
removal ofSDS, the gel was exposed to the PA, urokinase (UK), which 
activated the plasminogen to form plasmin. The plasmin degraded all 
gelatin incorporated in the gel except where inhibitors of PA (or plasmin) 
were present. The presence of inhibitors was detected as bands of gelatin 
remaining in a clear gel following staining for protein with amido black. 
The quantity of protein present in serum-free medium was not sufficient 
to be detected following staining with amido black. The bands at SO 
and 43 kDa represent bands of gelatin that were not degraded by uro-
kinase-activated plasmin. 
lase, 200 kDa; BSA, 66 kDa; carbonic anhydrase, 29 kDa) in a total 
volume of 0.25 ml on an 0. 7 x 60 cm column of Sephadex G-100 
previously equilibrated with PBS. The column was eluted with PBS at 
a rate of 0.5 ml/min, and 0.1 ml samples were collected. Samples were 
reacted for 60 min at 3Cl°C with 105 cpm 1251-UK prepared for SDS gel 
electrophoresis and autoradiography as described above. 
Serum-freeheart CM was concentrated 20-fold, and 0.5 ml was loaded 
along with molecular-weight standards (blue dextran, 2000 kDa; thy-
roglobulin, 670 kDa; amylase, 200 kDa; BSA, 66 kDa; carbonic an-
hydrase, 29 kDa) onto a 0.8 x 75 cm Sepharose 6B column previously 
equilibrated with PBS. The column was eluted with PBS at a rate of0.4 
ml/min, and 0.95 ml fractions were collected and reacted with 4 x 105 
cpm of 1251-UK for 60 min. Samples were then processed for SDS gel 
electrophoresis and autoradiography as described above. 
Octyl-Sepharose. The fraction eluted from a heparin affinity column 
containing the inhibitor (eluted at 0.7 M NaQ) was dialyzed against 10 
mM phosphate buffer, pH 7.4, and brought to 1.2 M ammonium sulfate 
and 0.1 mg/ml BSA. Samples (2-10 ml) were loaded onto an octyl-
Sepharose column (1 ml bed volume) previously equilibrated with 1.2 
M ammonium sulfate in 10 mM phosphate buffer, pH 7.4. Protein was 
eluted with a decreasing linear gradient of ammonium sulfate, followed 
by an increasing linear gradient of Triton X-100 to a maximum of 3% 
Triton X-100 in water. Samples were diluted to 0.2 M ammonium sulfate 
or 0.2% Triton X-100 prior to reacting with 1251-UK, electrophoresis, 
and autoradiography. Neither of these concentrations of reagents af-
fected the binding of m J-UK to the inhibitor. 
Heparinase treatment of heart CM 
Serum-free heart CM (20-fold concentrated) was incubated with 280 
.1£g/ml heparinase (catalog no. H 7505, Sigma) containing also -2% 
heparitinase and I% hyaluronidase activity (see Yang et al., 1985, for 
specificity ofheparinase) for 2.5 hr at 32°C. The sample was then loaded 
onto a Sepharose 6B column with appropriate molecular-weight stan-
dards and chromatography performed as described above. 
• 
Figure 2. Protein released by heart ceJls that binds PA. Serum-free 
CM from heart cell cultures was electrophoresed in a polyacrylamide 
gel and blotted onto nitrocellulose. The nitrocellulose was then probed 
with •isJ-UK followed by autoradiography. The band at 51 kDa rep-
resents a protein released by heart cells that binds 1251-UK. 
Neurite outgrowth studies 
Sympathetic neurons were plated onto Type I collagen at low density 
(50-100 cells/cm2) in 35 mm tissue culture dishes in serum-free L-15 
medium (see Cell culture). Neurons were grown for 18 hr in the absence 
or presence of a highly purified fraction of the heart inhibitor and then 
fixed with PBS containing 2% glutaraldehyde. Morphometric data were 
obtained on neurite outgrowth parameters using a computer-based 
videomicroscopy system consisting of an IBM XT computer, Dage New-
vicon video camera, Panasonic monitor, and Houston Hi-Pad. Neurite 
outgrowth parameters were obtained onJy from isolated neurons that 
did not contract other neurons or non-neuronal cells. 
Results 
PA activity in cocultures of sympathetic neurons and heart 
cells 
To determine the effects of a normal target tissue on neuronal 
PA activity, sympathetic neurons were grown in the presence 
of heart cells, and the amount of PA released into the culture 
medium was determined. Neurons cultured in the absence of 
heart cells released considerable PA, whereas little or no PA 
activity was detected in cocultures ofheart cells and sympathetic 
neurons (Table 1). A n umber of possibilities could explain this 
observation, including regulation of PA release by the target 
tissue or the release of an inhibitor of PA by heart cells. To 
investigate the second possibility, CM from neuron alone cul-
tures (containing PA) was mixed with CM from heart cell cul-
tures (source of potential inhibitor). This "mixing" experiment 
80K-
68K-
33K-
UK 
-
--
CM 
Figure 3. Complexes between 12s1-UK and proteins in serum-free heart 
CM. 12s1-UK was mixed with serum-free LIS medium (lane/, UK) or 
with serum-free CM from heart cell cultures (lane 2, CM) for 45 min 
at 3D°C followed by boiling in SDS, electrophoresis, and autoradiog-
raphy. 
indicated that the neuronal PA had little or no activity following 
incubation with heart cell CM (Table l). This finding suggested 
that an inhibitor of PA that inactivated the neuronal PA was 
being released by heart cells. 
Inhibitor released by cultures of heart cells 
A more direct assay for the presence of potential inhibitors in 
heart cell CM was developed (see Materials and Methods, In-
hibition method). In short, CM from heart cells was electropho-
resed in a polyacrylamide gel containing gelatin and plasmin-
ogen. The gel was then exposed to a solution of UK (the neuronal 
PA is a UK-like PA: Pittman, I 985a); this activated the plas-
minogen incorporated in the gel to form plasmin, which de-
graded the gelatin. Inhibitors (of either UK or plasmin) block 
the degradation of gelatin in specific areas of the gel and are 
detected as bands of gelatin in a clear gel. Using this assay, a 
major band of gelatin was present at SO kDa and a minor band 
at 43 kDa (Fig. 1). 
The possibility that additional molecules were released from 
heart cells that bound PA but did not inhibit its activity was 
investigated. Proteins released by heart cells were electropho-
resed, transferred to nitrocellulose, and "probed" with 1251-UK. 
Using this procedure a single protein with a molecular weight 
of 51 kDa was consistently found to bind 12s1-UK (Fig. 2). This 
51 kDa protein probably represents the 50 kDa inhibitor de-
scribed above. 
Complex formation between PA and heart proteins 
The above data indicated that heart cells were releasing at least 
one or possibly 2 proteins that bound PA and inhibited its 
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Figure 4. Separation of heart inhibitors following gel filtration on 
Sephadex G-100. Serum-free CM (0.25 ml) from heart cell cultures 
containing both fibroblasts and myocytes was concentrated 15-fold and 
loaded onto a 0.7 x 60 cm column ofSephadex G-100. The column 
was eluted with PBS at a rate of 0.5 ml/min, and 0.1 ml samples were 
collected. Samples were reacted with '2'1-UK for 60 min and then pro-
cessed for SDS gel electrophoresis and autoradiography. Bands corre-
sponding to the 68 kDa (O) and 80 kDa (•) complexes were cut out of 
the gels and the radioactivity detected using a gamma counter. Molec-
ular-weight standards are denoted by bold arrows: AL (amylase, 200 
kDa); BSA (bovine serum albumin, 66 kDa); and CA (carbonic anhy-
drase, 29 kDa). 
activity. Knowing the approximate molecular weights of the 
inhibitors (50 and 43 kDa) and that of 1251-UK (33 kDa), it was 
possible to look for the complexes formed between 125I-UK and 
the inhibitors. When 1251-UK was mixed with heart cell CM 
followed by PAGE and autoradiography, less radioactivity was 
present in the band at 33 kDa (1251-UK), and 2 new bands 
appeared at molecular weights of 80 and 68 kDa (Fig. 3). The 
complexes between 125I-UK and proteins released by heart cells 
were stable following boiling in SDS/ mercaptoethanol, which 
indicated that extremely stable complexes were being formed 
between 12$1-UK and the protein(s) released by heart cells. 
Properties of inhibitor(s) under native conditions 
The molecular weights of the heart inhibitor(s) following SDS-
PAGE were approximately 43 and SO kDa (Fig. !); however, 
these molecular weights may not reflect the state of the inhib-
itor(s) under physiological conditions. To determine if these 
inhibitors represented subunits of larger structures or if addi-
tional molecules were associated with them under native con-
ditions, heart cell CM was fractionated over Sephadex G-100 
and Sepharose 6B. Gel filtration chromatography of heart cell 
CM using Sephadex G-100 indicated that the heart inhibitor 
protein that formed a 68 kDa complex with 1251-UK migrated 
near 50 kDa (Fig. 4). The heart protein that formed the 80 kDa 
complex with mi-UK ran at the exclusion volume of the Seph-
adex G-100 column, which indicated that, in the absence of 
SDS, this protein had an apparent M, of > 150 kDa. This sug-
gested that the heart protein that formed the 80 kDa complex 
with 1251-UK was either associated with other macromolecules 
or was part of a multisubunit complex that dissociated following 
exposure to SDS. 
Fractionation of heart cell inhibitors on Sepharose 6B indi-
cated that the heart inhibitor that formed the 80 kDa complex 
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Figure 5. Separation of heart inhibitors following gel filtration on 
Sepharose 6B. Serum-free heart CM was concentrated 20-fold and 0.5 
ml ei1her loaded onto a 0.8 x 75 cm Sepharose 6B column (A) or 
incubated with 140 µg heparinase for 2.5 hr and then loaded onto a 
0.8 x 75 cm Sepharose 6B column (B). The column was eluted with 
PBS at a rate of 0.4 ml/min, and 0.95 ml fractions were collected and 
reacted with 1251-UK for 60 min and then processed for SDS gel elec-
trophoresis and autoradiography. Bands corresponding to the 68 kDa 
(O) and 80 kDa (e) complexes were cut out of the gel and the radio-
activity detected using a gamma counter. Less than 10% of the radio-
activity remained in the stacking gel, indicating that the inhibitor was 
released from the large-molecular-weight complex in the presence of 
SDS. Molecular-weight standards are denoted by bold arrows: BD, blue 
dextran (2000 kDa); TG, thyroglobulin (670 kDa); AM, amylase (200 
kDa); BSA. bovine serum albumin (66 kDa); CA. carbonic anhydrase 
(29 kDa). 
Figure 6. Separation of inhibitors fol-
lowing chromatography on heparin 
Sepharose. Serum-free heart CM (50 ml) 
was loaded onto a 0.6 x 4.5 cm hep-
arin-Sepharose column. The column 
was then washed with sequential 10 ml 
volumes of 50 mM Tris, pH 7.5, con-
taining 0, 0.1, or 0.3 M NaCl followed 
by 3 ml of 50 mM Tris containing 0.7 
or 1.0 M NaCl. A 0.01 ml sample of 
each fraction was adjusted to 0.2 M NaCl 
and reacted with 1251-UK, followed by 
electrophoresis and autoradiography. 
Lanes represent serum-free LIS medi-
um (UK), serum-free heart CM prior to 
chromatography (CM), heart CM that 
flowed through the heparin column 
(FT), protein eluted with 0.3 M NaCl 
(0.3 M), and protein eluted with 0.7 M 
NaCl (0. 7 M). Note that the band at 33 
kDa represents 1251-UK added to all 
samples, whereas the bands at 68 and 
80 kDa represent complexes between 
m1-UK and proteins released by heart 
cells. No complexes were present at 0, 
0.1, and 1.0 M NaCl; therefore, these 
samples are not included in the figure. 
80K-
68K-
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U K 
with 1251-UK migrated ahead of dextran blue, suggesting a mo-
lecular weight of >2 x 106 Da (Fig. 5A). To investigate other 
potential components of this macromolecular complex, a sam-
ple of heart cell CM was treated with heparinase followed by 
fractionation over a Sepharose 6B column. Heparinase treat-
ment decreased the amount of protein that migrated with a 
molecular weight of > 2 x l 06 Da by about 70% and increased 
the amount of protein that eluted with low-molecular-weight 
components by a comparable amount (Fig. SB). Of particular 
significance was that the increase in the low-molecular-weight 
component following heparinase treatment resulted in an in-
crease in the amount of the 68 kDa complex and not in the 80 
kDa complex. This suggested that a single inhibitor might be 
present that formed a 68 kDa complex with 1251-UK in the 
absence of heparan sulfate proteoglycan and an 80 kDa complex 
in its presence. 
Interactions of the heart inhibitor with heparin 
The experiments with heparinase suggested that under phys-
iological conditions, the inhibitor could interact with heparin 
sulfate proteoglycans; therefore, the interaction of the inhibitor 
with heparin was investigated by fractionating heart cell CM on 
a heparin Sepharose column. The heart inhibitor that interacted 
with 1251-UK to form the 68 kDa complex bound quantitatively 
with high affinity to heparin Sepharose, whereas the heart pro-
tein that formed the 80 kDa complex did not bind to the hep-
arin-Sepharose column (Fig. 6). Because of its association with 
a large macromolecular complex that probably included heparan 
sulfate proteoglycan, this form of the inhibitor may not have 
had access to the heparin bound to the Sepharose matrix. 
Advantage was taken of the finding that 2 forms of the in-
hibitor could be quantitatively separated on a heparin Sepharose 
column. This allowed experiments to be performed to determine 
the effects of heparin on complex formation. 
Heart cell CM was fractioned using heparin Sepharose into a 
fraction containing the inhibitor that formed the 80 kDa com-
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Figure 7. Effect of heparin on 80 kDa (A) and 68 kDa (B) protease-
inhibitor complex formation. Serum-free heart CM was fractionated 
using heparin-Sepharose into a fraction containing the inhibitor that 
formed the 80 kDa complex (the flow-through fraction) and a fraction 
containing the inhibitor that formed the 68 kDa complex (the fraction 
eluted with 0. 7 M NaCl). Each fraction was adjusted to 0.2 M NaCl and 
incubated with 12sI-UK in the absence (0) or presence (e) of 0.5 mg/ 
ml heparin. Aliquots were removed at the indicated times, boiled in 
SDS/mercaptoethanol, and electrophoresed. Bands corresponding to the 
68 and 80 kDa complexes were cut from the gels and the radioactivity 
determined. Data represent averages of 2 experiments. 
plex (the flow-through fraction) and a fraction containing the 
inhibitor that formed the 68 kDa complex (eluted from the 
column with 0. 7 M NaCl). Each fraction was tested to determine 
the effect of heparin on complex formation with 1251-UK. H ep-
arin had no effect on the formation of the 80 kDa complex (Fig. 
7 A), whereas the presence of heparin increased the amount of 
the 68 kDa complex formed (Fig. 7 B). In addition to increasing 
the amount of the 68 kDa complex, the presence of heparin also 
resulted in the formation of a small amount of an 80 kDa com-
plex between 1251-UK and the inhibitor in the fraction eluted 
from the heparin affinity column (Fig. 8). This supports the data 
presented in Figure 5 and suggests that the 2 heart inhibitors 
are the same protein and that in the presence of heparin or 
heparan sulfate proteoglycan a stable 80 kDa complex is formed 
with 1251-UK. In the absence of heparin or heparan sulfate pro-
teoglycan, a 68 kDa complex appears to be formed. Although 
some 80 kDa complex was formed when the partially purified 
inhibitor was incubated with 12s1-UK in the presence of heparin, 
it was not a quantitative conversion from the 68 kDa complex 
to the 80 kDa complex. The reason for this is unclear, although 
heparan sulfate proteoglycan may stabilize the 80 kDa complex 
better than heparin or other components in the large proteogly-
can complex may be involved in the formation of the 80 kDa 
complex. 
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Figure 8. Formation of some 80 kDa complex between ml-UK and 
the inhibitor eluted from the heparin-Sepbarose column. The inhibitor 
that bound to the heparin-Sepbarose column was eluted with 0. 7 M 
NaCl and incubated with 1251-UK in the presence and absence of heparin 
as described in Figure 8. In the absence of heparin (O), no 80 kDa 
complex was formed, whereas in the presence of0.5 mg/ml heparin (e ), 
some 80 kDa complex was formed between 12s1-UK and the inhibitor 
eluted from the heparin-Sepharose column. Heparin alone without the 
column fraction (0) did not form 80 kDa complex with ' "I-UK. These 
data were taken from the same gels as data in Figure 7. Data represent 
averages of 2 experiments. 
Inhibitor associated with cardiac myocytes and fibroblasts 
Because heart cell cultures are comPosed of both myocytes, 
which are a normal target for sympathetic neurons, and fibro-
blasts, which are not, it was of interest to determine if the in-
hibitor was associated with cardiac myoctyes. Highly enriched 
populations of both cardiac myocytes and fibroblasts were pre-
pared. Conditioned medium from each cell type totally inhibited 
neuronal PA activity (not shown), and both cell types released 
proteins that formed extremely stable complexes with 1251-UK 
80K-
68K-
33K-
-
1 
-
2 
Figure 9. Complex between 1251-UK and proteins in serum-free me-
dium from cardiac fibroblasts (lane 1) and cardiac myocytes (lane 2). 
Samples of serum-free CM from cultures containing predominantly 
cardiac fibroblasts or cardiac myocytes were incubated with 12s1-UK 
and then processed for electrophoresis and autoradiography. Note the 
enrichment of the 80 kDa complex in fibroblast CM and the enrichment 
in the 68 kDa complex in the myocyte CM. 
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Figure I 0. Elution of the inhibitor from octyl-Sepharose. The inhibitor 
was eluted from a heparin-Sepharose column with 0. 7 M NaCl, dialyzed 
against 10 mM phosphate buffer, pH 7.4, and brought to 1.2 M am-
monium sulfate and 0.1 mg/ml BSA. A 4.0 ml sample was loaded onto 
a I ml octyl-Sepharose column equilibrated with 1.2 M ammonium 
sulfate in 10 mM phosphate buffer, pH 7.4. Protein was eluted with a 
decreasing linear gradient of ammonium sulfate, followed by an in-
creasing linear gradient of Triton X-100. Samples were diluted to 0.2 
M ammonium sulfate or 0.2% Triton X-100, reacted with 1251-UK, and 
electrophoresed, and the radioactivity was determined in the 68 kDa 
band. 
(Fig. 9). The inhibitor from cultures enriched in fibroblasts 
formed an 80 kDa complex with 1251-UK(Fig. 9, lane l), whereas 
the inhibitor from cultures enriched in myocytes formed pri-
marily the 68 kDa complex (Fig. 9, lane 2). 
Protease selectivity of the inhibitor 
An indication of the types of proteases that bind the heart in-
hibitor was obtained by preincubating heart cell CM with vary-
ing concentrations of proteases, followed by incubating samples 
with 1251-UK (Table 2). The ability of the added proteases to 
b lock the formation of the 68 and/or 80 kDa complexes with 
Table 2. Ability of proteases to block binding of m1-UK to heart 
inhibitors 
EC50 (OM) 
68 kDa 80 kDa 
Protease complex complex 
Thermolysin > WOO > 1000 
Aminopeptidase M > WOO > 1000 
Trypsin 7 6 
Chymotrypsin 11 14 
Plasm in 3 3 
Urokinase 4 6 
Thrombin 9 > 1000 
Data are the average of 2 experiments. ECso is the concentration of protease that 
d ecreased complex forma1ion of inhibitors with "'I-UK by 50%. Heart CM was 
incubated with the indicated proteases (0.3, I, 3, I 0, 30, I 00, I 000 nM) for 60 min 
at 300<:' prior to incubation with " 'I-UK for 60 min. Bands corresponding to the 
68 and 80 kDa complexes were cut out of the gel and the radioactivity determined. 
116K 
97K 
66K 
45K 4mt 
29K 
1 
Figure 11. Highly purified preparation of heart inhibitor. The PA in-
hibitor was purified from heart cell CM by 2 passes over a heparin-
Sepharose column as described in Materials and Methods. Molecular-
weight markers were loaded in lane 1 (galactosidase, 116 kDa; phos-
phorylase, 97 kDa; BSA, 66 kDa; ovalbumin, 45 kDa; carbonic anhy-
drase, 29 kDa) and S µ.g of protein eluted from the second heparin-
Sepharose column was loaded into lane 2. Proteins were separated in a 
7% SDS-polyacrylamide gel in the presence of 4% 2-mercaptoethanol 
and silver-stained according to the procedure of Merril et al. ( 1981 ). 
125 1-UK was taken as a measure of their ability to compete for 
the inhibitor. Non-serine proteases (thermolysin and amino-
peptidase M) did not block the formation of either complex, 
whereas the serine proteases urokinase, trypsin, chymotrypsin, 
plasmin, and thrombin were about equally effective on blocking 
the formation of the 68 kDa complex. Formation of the 80 kDa 
complex was blocked by preincubation with UK, trypsin, chy-
motrypsin, and plasmin but not by thrombin. 
Comparison of the heart inhibitor with other inhibitors of 
serine proteases 
A number of inhibitors have been described that form stable 
bonds with various serine proteases (Chandra and Bang, 1977; 
Owen, 1975; Johnson and Travis, 1976; Baker et al., 1980; 
Loskutoff et al., 1983; Guenther et al., 1985; Parker and Tol-
lenfsen, 1985). The properties of the heart inhibitor described 
in the present studies including its molecular weight and ability 
to bind to heparin-Sepharose are most similar to the protease 
inhibitor, protease nexin (Baker et al., 1980). To compare the 
properties of the heart inhibitor in the present study with pro-
tease nexin, the binding of the heart inhibitor (eluted from a 
heparin affinity column with 0. 7 M NaCl) to octyl-Sepharose 
was investigated. When protease nexin is loaded on octyl-Sepha-
rose in 1.2 M ammonium sulfate it elutes at 0. 7 M ammonium 
sulfate (Scott and Baker, 1983), whereas the heart inhibitor un-
der investigation in the present study does not elute from octyl-
Sepharose at any ammonium sulfate concentration and is eluted 
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Figure 12. Effect of the heart inhibitor 
on neurite outgrowth. Sympathetic 
neurons were plated in the absence or 
presence of0.5 µgiro! (i;;;J) or 5.0 µg/ml 
(ffi) of a highly purified preparation of 
the heart inhibitor (see Fig. 11 and Ma-
terials and Methods) for 18 hr. Neurons 
were then fixed in PBS containing 2% 
glutaraldehyde and morphometric data 
obtained as described in Materials and 
Methods. Primary processes are those 
neurites that are directly connected to 
the cell body, whereas secondary and 
tertiary processes are defined as neu-
rites that branch from primary and sec-
ondary neurites, respectively. Data rep-
resent means ± SEM of 50-200 neurite 
lengths (for each process type and ex-
perimental condition) taken from 18 
dishes of neurons. 
process type 
• control 0.5 ug/ml [1] 5.0 ug/ml 
only in the presence of high concentrations of detergent (Fig. 
10). Even on a less hydrophobic column such as pentyl-Sepha-
rose, detergent (0.5-1.0% Triton X-100) was required to remove 
the heart inhibitor (not shown). These experiments indicate that 
although many of the properties of the heart inhibitor are similar 
to protease nexin, the inhibitor appears to be a much more 
hydrophobic protein. 
Effect of the inhibitor on neurite outgrowth 
The inhibitor present in heart cell CM was purified by 2 passes 
over a heparin-Sepharose column (see Materials and Methods). 
The purity of the protein eluted from the second column was 
>95% based on SDS gel electrophoresis (Fig. 11). Its molecular 
weight of 50 kDa agrees well with the molecular weight obtained 
by probing blotted proteins with 1251-UK (Fig. 2). The 50 kDa 
protein forms a 68 kDa complex with UK but does not form a 
complex with DFP-treated UK (not shown). A 2- to 3-fold 
increase in neurite outgrowth occurred when sympathetic neu-
rons were grown in the presence of the highly purified inhibitor 
(Fig. 12). The outgrowth of primary, secondary, and tertiary 
processes were all increased by the inhibitor in a dose-dependent 
manner (Fig. 12). 
Discussion 
Sympathetic neurons release a UK-like PA from distal processes 
and/or growth cones (Pittman, 1985a). The present study was 
undertaken to determine whether growing sympathetic neurons 
in the presence of heart cells affected the amount of PA released. 
Initial studies indicated that little or no PA activity was present 
in cocultures of neurons and heart cells and that this appeared 
to be due to the presence of a PA inhibitor released by the heart 
cells. It did not appear that the inhibitor was a component of 
the fetal calf serum used to establish the cultures of heart cells. 
This was based on the following: ( 1) Although fetal calf serum 
has 3 proteins that form stable complexes with 1251-UK, none 
of these complexes have a molecular weight of 68 or 80 kDa; 
(2) highly purified cultures of fibroblasts and myocytes were 
established in the total absence of serum and were grown for 
2-3 weeks in serum-free medium with no decrease in the pro-
duction of the inhibitor; and (3) the sustained release of the 
inhibitor into the culture medium was dependent on EGF or 
phorbol ester in the serum-free medium. Biochemical charac-
terization of the heart inhibitor has been carried out as a first 
step in determining if this protein has a function in neurite 
outgrowth dynamics and neuron-target cell interactions. 
A number of different cell types release inhibitors of serine 
proteases (Eaton and Baker, 1983; Van Mourik et al., 1984; 
Guenther et al., 1985). The function of these inhibitors is un-
known; however, it has been suggested that they protect cells 
from serine proteases released under normal and/ or pathological 
conditions. Work from Monard's laboratory has shown that one 
such inhibitor of serine proteases is released by glioma cells and 
increases process outgrowth from neuroblastoma cells (Monard 
et al., 1983; Guenther et al., 1985; Monard, 1985). 
Two inhibitors or one? 
In the early phases of this work it appeared that 2 inhibitors 
were being released by heart cells. One had a M, of approxi-
mately 43 kDa, was released primarily by myocytes, and formed 
a 68 kDa complex with 1251-UK. The other inhibitor had a M, 
of about 50 kDa, was released primarily by fibroblasts, and 
formed an 80 kDa complex with 1251-UK. Further biochemical 
analysis of these 2 proteins, however, suggested that they may 
be two forms of the same protein. The protein that formed the 
80 kDa complex with 1251-UK migrated with an apparent M, of 
> 2 x 106 Dain the absence ofSDS, whereas following heparin-
ase treatment, it had an apparent M, of about 50 kDa and formed 
a 68 kDa complex with 1251-UK. The protein that formed the 
68 kDa complex with 1251-UK formed a small amount ofan 80 
kDa complex in the presence of heparin. These 2 observations 
are most consistent with there being a single inhibitor protein 
with a M, of approximately 50 kDa. During its interaction with 
1251-UK, it is likely that a 6-10 kDa piece of the inhibitor is 
cleaved as one of the steps leading to the extremely stable com-
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plex that is formed between the inhibitor and UK. It has been 
shown for the serine protease inhibitors antithrombin III, a-1-
proteinase inhibitor, and protease nexin that a 6-10 kDa piece 
of the inhibitor is Jost during complex formation (Johnson and 
Travis, 197 6; Chandra and Bang, 1977; Scott and Baker, 1983). 
The 6-10 kDa polypeptide may not be cleaved from the heart 
inhibitor ifthe inhibitor is bound to heparin or heparan sulfate 
proteoglycan. The ability to maintain the 6-10 kDa polypeptide, 
as well as formation of a stable complex with a serine protease, 
has not been described for other protease inhibitors, however. 
The fact that a small amount of a 43 kDa inhibitor was de-
tected in CM following gel electrophoresis (Fig. 1) would suggest 
that 2 inhibitors exist. However, it has been shown for protease 
nexin that electrophoresis in Tris buffer (as was done in the 
present studies) results in the dissociation of a small amount of 
the protease-inhibitor complex and a concomitant loss of 6 kDa 
in the M, of the inhibitor (Scott and Baker, 1983). This could 
account for the 2 "apparent" inhibitors in Figure 1. If only one 
inhibitor is present in heart CM, then the inability ofthrombin 
to inhibit the 80 kDa complex formation (Table 2) could be 
explained by the binding of thrombin to the heparan sulfate 
proteoglycan in this preparation (it is known that thrombin 
binds to heparin), which results in a decrease in the free con-
centration of thrombin available to interact with the inhibitor. 
It is still possible that 2 different inhibitors are released by heart 
cells; however, until large-scale purification of the inhibitor is 
performed, definitive experiments will not be possible. 
Inhibitor as a constituent of heart CM and its effect on neurite 
outgrowth 
Heart cell CM is an excellent source of substrate-attached neu-
rite outgrowth factors (Collins, 1978; Dribin and Barrett, 1980; 
Adler et al., 1981; Coughlin et al., 1981). Neurite-promoting 
factors in CM from non-neuronal cells have been identified as 
laminin, heparan sulfate proteoglycan, and a combination of 
these molecules (Lander et al., 1982, 1985; Coughlin et al., 
1986). Because of the apparent high affinity of the heart inhibitor 
for heparin, it is reasonable to assume that another normal 
constituent of these substrate-attached neurite outgrowth factors 
is the inhibitor characterized in the present study. Heart cell 
CM prepared and exposed to tissue culture dishes essentially as 
described by Collins (1978) contains a significant amount of the 
inhibitor (unpublished observations). In addition, a highly purified 
preparation of the heart inhibitor increases neurite outgrowth 
from sympathetic neurons (Fig. 12). Therefore, it appears that 
the heart inhibitor is a normal constituent of substrate-attached 
neurite outgrowth factors from heart CM and may participate 
in and/or modulate the events resulting in enhanced neurite 
outgrowth. 
Although the heart inhibitor binds the neuronal PA and in-
hibits its activity, it also binds other serine proteases (Table 2). 
Therefore, its effect on neurite outgrowth may not involve the 
neuronal PA, but rather another serine protease associated with 
the neuron. 
Significance of the heart inhibitor in nervous system 
development 
The heart inhibitor increases neurite outgrowth from sympa-
thetic neurons (Fig. 12); therefore, it may have a direct or mod-
ulatory role in neurite outgrowth in vivo. In addition, the in-
hibitor may be involved in neuron-target interactions. 
Sympathetic neurons release the serine protease PA from grow-
ing neurites (Pittman, l 985a), and a normal target tissue of 
sympathetic neurons (heart cells) releases an inhibitor of PA 
(present study). The possibility that neuron-target cell interac-
tions may involve protease-inhibitor interactions is particularly 
intriguing; however, it must be realized that cardiac fibroblasts 
also release the inhibitor. Therefore, protease-inhibitor inter-
actions would not be expected to be involved in target recog-
nition, but rather in an event such as decreasing local proteolytic 
activity so that synaptogenesis could occur. In its simplest form, 
target cell inhibitors could be used to convert a proteolytically 
active system, which is useful for neurite outgrowth, to a less 
active system in which synaptogenesis can proceed. Once syn-
apses were formed, it might be expected that retrogradely trans-
ported factors from the target cells would instruct the neuron 
to down-regulate proteolytic activity; however, until this oc-
curred, local control of proteolysis during active synaptogenesis 
would be performed by target cell inhibitors. The possibility 
that more complex interactions may be occurring is suggested 
by recent observations indicating that sympathetic neurons have 
a surface protein that binds PA (Pittman, 1985b). Therefore, 
once the growing neurite approached its target, there would be 
a competition between the heart inhibitor and the neuronal 
surface protein for the neuronal PA. 
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